RTX-224 Monotherapy in Patients With Solid Tumors

NCT05219578 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

Enrollment

INDUSTRY

Sponsor class

Stopped The Sponsor terminated study after dosing 2 dose groups (7 pts) and closed trial on 11/30/22. RTX-224 was well-tolerated with no DLTs, no related deaths, SAEs or Gr. 3/4 AEs and cleared rapidly (w/in 10 min).

Conditions

Non Small Cell Lung Cancer
Cutaneous Melanoma
Head and Neck Squamous Cell Carcinoma
Urothelial Carcinoma
TNBC - Triple-Negative Breast Cancer

Interventions

DRUG: RTX-224

Sponsor

Rubius Therapeutics